Related by context. All words. (Click for frequent words.) 75 xviii 73 xvii 71 xxi 71 xxii 70 xvi 70 xiii 69 viii 66 xii 66 xxv 66 xiv 65 xv 65 vii 64 xxiii 63 ix 62 xxvi 61 iv 61 iii 59 xxiv 59 xi 59 xxvii 58 vi 57 risksassociated 57 xxviii 56 Immtech clinical trials 55 Immtech scientists 55 ii 54 legal proceedings xxi 53 Pure Biofuels ability 52 regarding Heska 52 materially adversely affect 52 xxxiii 51 ourability 51 SeraCare competitors 51 adverse determinations 50 multiple lease terminations 49 governmental approvals 49 EMPOWER pivotal trial 49 xxxii 48 substantial indebtedness 48 successfully integrate 48 unanticipated difficulties 48 otherfactors 48 affecting Amarin 48 DSL.net s 48 collect reinsurance recoverables 48 OSI Pharmaceuticals filings 48 risks associatedwith 47 unanticipated 47 requirements xxii 47 orotherwise 47 technological obsolescence 47 PharMerica LTC Transaction 47 deploy MDCE services 47 ability tosuccessfully 47 general economicconditions 47 lender consents 47 nonoccurrence 47 risks anduncertainties 47 HealthGate ability 47 Projects Initiation 47 incur unanticipated 47 candidate Ramoplanin 46 xxix 46 otherrisks 46 affecting mortality morbidity 46 vii IBC 46 i# implanters 46 thereby negatively impacting 46 HANA MAX 46 theability 46 relatedto 46 Crisa acquisition 46 rapid technological 46 work stoppages quarantines 46 Unitholder liability 46 Somaxon ability 46 withrespect 46 market fluctuations investee 46 Mago ® 46 sites xix limitations 45 SumTotal Systems filings 45 pricing pressures 45 contingent guaranties 45 suchforward looking 45 TranSwitch indebtedness 45 REIT xi 45 notlimited 45 xiv unanticipated 45 adversely affecting Cubist 45 differ materiallyfrom 45 obtaining regulatory approvals 45 vii viii 45 market PolyHeme commercially 45 vii Cubist ability 45 without limitation 45 Heska reliance 45 relating 45 VIOXX Lawsuits 45 PD2i Cardiac Analyzer 45 SANCTURA SANCTURA XR VANTAS 45 ofsuch 45 orother 44 successfully commercialize 44 changesin 44 filingswith 44 refinance indebtedness 44 offerings visit www.balqon.com 44 manufacture PolyHeme 44 causeactual results 44 OneBeacon filings 44 Waratah Coal filings 44 retrocessional coverage 44 unanticipated geological 44 SUPPRELIN LA DELATESTRYL 44 including withoutlimitation 44 adversely affect 44 results ofoperations 44 uncertainties 44 work stoppages slowdowns 44 Prelude SkinPrep Systems 44 contingently liable 44 date xvii Conversion 44 limitedto 44 Equinix filings 44 related thereto 44 cadence regulatory approvals 44 theCompany 44 Item IA 44 arenot limited 44 PLIVA acquisition 44 communicate differentiations effectively 44 involverisks 44 ourproducts 44 PLAVIX R patent 43 iii Cubist 43 adversely affect Univest Corporation 43 deCODE filings 43 Questcor intellectual property 43 without limitation Terremark 43 successfully commercialize Silenor 43 Fampridine SR Acorda Therapeutics 43 CAUTION ANY ATTEMPT 43 uncertaintiesthat 43 Daytrana TM 43 PDI periodic filings 43 FierceGovernmentIT tracks 43 thereunder 43 commercialize ZYFLO CR 43 maycause actual results 43 ExchangeCommission 43 Secure Computing periodic 43 expropriation nationalization 43 affirmative covenants 43 prepayment speeds loan originations 43 tenant bankruptcies 43 [013] 43 risks associated 43 Protonix ® 43 incurrence 43 impactof 43 Form 8K #K 43 Oxandrin R 43 xiv licensing 43 ofnew 43 PD2i Analyzer 43 timing rescheduling 43 e# periodic 43 ENABLE Phase 2 43 materially adversely affected 43 ultimate recoverability 43 intercompany arrangements 43 Black Canyon mica 43 MGCD# MGCD# [002] 43 BiDil XR drug 43 couldcause actual results 42 Cerro Negro concession 42 SANCTURA SANCTURA XR NEBIDO 42 SURETY LICENSES c 42 reinsurance recoverables owed 42 economicconditions 42 BioSante licensees 42 risks unanticipated reclamation 42 permitting timelines 42 risksand uncertainties 42 EHSK 42 h g 42 xv licensing 42 technological innovations adversely affecting 42 inventory obsolescence 42 mergers dispositions 42 expenses associated therewith 42 party VLSI fabrication 42 affecting Pennichuck Corporation 42 adverse 42 examinations vaccinations spaying 42 currency fluctuations imprecision 42 postretirement benefit obligations 42 d Reflects 42 MethyPatch 42 TP# CETi 1 42 risks associated therewith 42 consolidations restructurings bankruptcies 42 Candente relies upon 42 Gastroesophageal Reflux 42 vii Dynamic 42 purchaserâ € ™ 42 inaccurately estimating 42 gastrointestinal GVHD include 42 novel therapeutic modality 41 areforward looking 41 refund guarantors 41 Shire plc Attention Deficit 41 consummating acquisitions 41 indebtedness covenant 41 xvi beer 41 Zanaflex Capsules 41 current physiologic opioid 41 workersa compensation 41 differ materially fromthose 41 Entereg TM 41 infringed misappropriated invalid 41 CCR5 inhibitors entry 41 sublicense agreements 41 tarmac strandings Hanni 41 Yima project 41 incorporate proprietary Microvolt 41 OraTest R 41 especially Copaxone ® 41 Risks uncertainties 41 theavailability 41 adversely affecting 41 Silver Wheaton purchases 41 RAPIDGate Program contains 41 statementsregarding 41 Oxandrin ® 41 Insolvency Proceedings 41 u t 41 prices drydocking 41 Nortel unfunded 41 SonoPrep device 41 CORLUX CORT # 41 MGCD# MGCD# [001] 41 SmarTire dependence 41 SANCTURA R 41 xxvi introduction 41 AspenTech periodic reports 41 CompanyaEUR TM s 41 molecular immunohematology 41 aresubject 41 unitholder liability 41 heading ITEM 1A 41 Bioenvision filings 41 c SIGA 41 Thalomid R 41 Sepracor anticipates 41 Merger Transactions 41 cause actualresults 41 depreciation depletion amortization 41 differmaterially 41 Puricase PEG uricase 41 Optimer filings 41 BeadArray TM VeraCode 41 ALICO Holdings 41 Shire Attention Deficit 41 adversely affect Waste Connections 41 actualresults 41 Direct Indirect x 41 minerals inc 41 Durus Life 41 cranes Fuchs 41 pharmacotherapeutics 41 andgeneral 41 Johnell O 41 sites xviii limitations 41 adversely affect FNB 41 filedwith 41 Form #KSB filed 41 Omtool periodic reports 40 site www.buyins.net 40 Genitope Corporation filings 40 affect Petroflow 40 STRIANT R 40 successfully commercialize REOLYSIN 40 Rexahn actual 40 EVIZON TM squalamine lactate 40 viii inability 40 CompX 40 obsolete inventory 40 arising therefrom 40 Iusacell Celular 40 excimer laser atherectomy 40 CholeraGarde R Peru 40 TranSwitch filings 40 securityholder approvals 40 principally attributable 40 n h 40 PolyHeme successfully 40 - -Billeaudeau 40 CDO financings 40 anyforward looking 40 d Represents 40 Lenfest ii 40 infringement invalidity 40 differ materially 40 r l 40 Excluding acquisitions divestitures 40 PGP Acquisition 40 PD2i Analyzer ™ 40 Alnylam dependence 40 HealthTronics periodic filings 40 materially impair 40 personnel xviii inability 40 party semiconductor foundries 40 uncertainties materializes FICO 40 LPM TM 40 competing steel minimills 40 sequencing gene expression 40 P. #a 40 Web site http:/www.EmergingStockReport.com 40 Textainer expectation 40 MTI MTI Micro 40 #.#-# b [002] 40 personnel xvii inability 40 fluctuations 40 PD2i ® algorithm 40 representations warranties covenants 40 SearchHelp communications 40 Enpath ability 40 successfully commercialize Iluvien 40 persistency mortality 40 TRISENOX R 40 Company periodic filings 40 inherent uncertainty 40 VimpelCom disclaims 40 activate telomerase 40 treatment emergent hyperglycemia 40 maydiffer materially 40 party payors 40 f h 40 ADSI reliance 40 disinterested Shareholder approval 40 OPAXIO pixantrone 40 Symphony tCGM 40 Auxilium anticipates 40 Accurel 40 Securities andExchange Commission 40 surgery gynecology neurosurgery 40 website www.PennyStockAlley.com 40 RR Donnelley periodic filings 40 regulatory authorizations 40 REMOVAL Removal shall 40 dimesylate Attention Deficit 40 futureresults 40 love veronica Mars 40 andother 40 IMPAX filings 40 toreflect 40 sublease recoveries 40 Atheros Quarterly Report 40 Sirna concentration 40 chemosaturation system 40 cardiorespiratory diagnostic products 40 abilityto 40 i g 40 molecular immunohematology products 39 Ferlay J et al 39 natural disasters epidemics 39 § #.#-# [007] 39 collectibility 39 visit http:/www.nationwide.com 39 t r 39 Fampridine SR delays 39 Lignol files 39 torsemide ER 39 incidental thereto 39 ISX Data.com uses SafeDinar 39 o l 39 HF Lenfest member 39 NxStage anticipates 39 promulgated thereunder 39 retrocessional reinsurance 39 Varvarinskoye Project 39 y u 39 CompAir acquisition 39 permits consents 39 adversely impacting 39 Company noncontributory defined 39 currency fluctuations 39 distinguishing GigaBeam products 39 DARA intellectual property 39 CoStar stent 39 opioid tolerance 39 APTIMA HPV assay 39 CFR #.#b 39 heading RISK FACTORS 39 Filtran Microcircuits Inc. 39 arising 39 Exelbine 39 Entrust periodic 39 products visit www.adm.com 39 JLG acquisition 39 SuperStitch R 39 xxxi 39 couldcause 39 TRIOLEX HE# APOPTONE HE# 39 TriPath Oncology 39 Rexahn licensees 39 InfoSearch filings 39 BioGlue ® 39 Monovisc 39 c html plugins 39 c Relates 39 Theseforward looking 39 intellectualproperty 39 Second Supplemental Indenture 39 KRYSTEXXA TM 39 reserve estimations 39 AcryMed technologies 39 cancellations rescheduling 39 MAb therapy 39 Acorda Therapeutics intellectual property 39 DIP Loan 39 Sunesis nonclinical studies 39 Terremark filings 39 EPIXTAR 'S 39 SciClone filings 39 render PolyHeme obsolete 39 EPIX Pharmaceuticals 39 Disruptions uncertainty 39 HYVISC R 39 competitively procured pursuant 39 Company nanocrystalline materials 39 commercialize technological innovations 39 Synvista Therapeutics filings 39 website www.FreePennyAlerts.com 39 Securitiesand Exchange Commission 39 Cautionary Disclosures 39 impacting WesBanco 39 Favrille filings 39 § #.#-# [004] 39 relapsed acute myelogenous 39 oxandrolone USP 39 BOPET film industry 39 Nephros filings 39 Neurokine 39 BugOil R 39 Avivo Corporation 39 Market Disruption 39 detrimentally impacts 39 r h 39 EGRIFTA TM 39 should consult NeurogesX 39 liabilities slippage 39 Safe Harbors created 39 AudioCodes filings 39 tivozanib AV 39 VIOXX Product 39 website www.gladiatorstocks.com 39 GEROVA underwrites insurance 39 successfully integrate Legerity 39 Jupiterimages respective 39 Non Correlation 39 FSAH 39 Refinancing Transactions 39 reinsurance ceded 39 g o 39 adversely affect Linktone 39 i #.# subds 39 Navios Partners filings 39 xx 39 Alpine Skiing Riding 39 paul dev da 39 productsand services 39 materially differ 39 capture exosomes 39 attribution authenticity provenance 39 BioForce Nanosciences actual 39 ecommerce marketplaces 39 debt extinguishments 39 uncertainties materialize Shire plc 39 recompetes 39 associated therewith 39 ceded reinsurance 39 substantiate CytoCore expectations 39 Tronox Annual Report 39 looking statements.Such 39 theforward looking 39 PAIVIS actual 39 xi unanticipated 38 OTC ZEGERID 38 retail industries repositionings 38 AngelCiti expectations 38 Vion filings 38 postretirement benefit plans 38 Pharmion Quarterly Report 38 commercialized Analyte Specific Reagents 38 AUCTIONEER CONSIGNOR OR 38 Oligator R oligonucleotides iv 38 cash fl ows 38 EAHA shall automatically 38 unforeseen underperformance 38 andour 38 u h 38 franchisees licensees 38 Verint Systems Inc 38 plastic photochromic lens 38 Indentures governing 38 anduncertainties 38 prepayment speeds loan 38 regardingthe 38 theSecurities 38 Verena filings 38 Bioenvision dependence 38 APNB 38 dispositions joint ventures 38 y h 38 looking statementswithin 38 inadequately insured 38 iii iv 38 vi vii 38 l o 38 Liability Lawsuits 38 PD2i Analyzer TM 38 unfavorable geologic 38 website StockPreacher.com 38 FastFunds Financial Corporation 38 vQsQn 38 Metabasis dependence 38 requisite stockholder 38 qW 38 withoutlimitation 38 XL# anticancer compounds 38 accounting pronouncements 38 Form# K 38 deploy GigaBeam 38 v Dot VN 38 marketconditions 38 HandHeld Entertainment filings 38 cause actual resultsto 38 periodic redeterminations 38 manufacture RISPERDAL CONSTA 38 EcaFlo ® equipment 38 periodic reports 38 Proposed Financing 38 diminishing quantities 38 xii trademark 38 suchstatements 38 includingstatements regarding 38 Duska intends 38 proprietary Capillary Aerosolization Technology 38 h r 38 Pharmos filings 38 enforce MOSAID 38 Oxandrin 38 Company website www.jcrew.com 38 collectability 38 Partially offsetting these 38 c Reflects 38 Westell accounting 38 Bioaccelerate compounds under 38 Solexa ® 38 USC § #a [002] 38 Analysis C.1 Strengths 38 intercompany indebtedness 38 Kyowa Kirin 38 economically recoverable coal 38 bioresearch monitoring 38 www.bpzenergy.com provides additional 38 Teva Annual Report 38 ii ultrasonic 38 GrowthWorks refers 38 DISMISSED WITH PREJUDICE 38 Chase Kishner 38 VanceInfo filings 38 Liquor Stores LP 38 reasonably determinable 38 VYVANSE TM lisdexamfetamine 38 Compans 38 ELEVESS 38 relating thereto 38 Illumigen Biosciences Inc. 38 title taxation sociopolitical 38 x Immtech 38 DTR #.#.# b 38 concerning Timminco 38 GenVec filings 38 positive inotropic agents 38 Sepracor patents 38 PMACIC 38 BY AN ENTRANT 38 #,#,# #,#,# -DH Ellis Burks 38 n h r 38 #.# subd [003] 38 website StockMarketLife.com 38 Thomas Regout operations 38 d h 38 embolic coiling 38 transactions contemplated 38 integrate CyVera technology 38 Charlie Manuel flips 38 dispositions financings 38 constitutes discloseable transaction 38 geology continuity 38 theseforward looking 38 Vion Annual Report 38 caption Management Discussion 38 currency fluctuation 38 visit www.adm.com 38 Ceragon Annual Report 38 serious cardiovascular thrombotic 38 FASEB enhances 38 pandemics impacting 38 CAUTIONARY STATEMENT Statements 38 visit www.targanta.com 38 partner lorcaserin APD# 38 tosuccessfully 38 borrower depositor 38 Plenaxis R 38 R Lotrel 38 Phyto Source LP 38 awakening feeling unrefreshed 38 Eligard R 38 DFAR #.#-# 38 TeamStaff filings 38 r t 38 looking statementsare 38 Atheros Annual Report 38 thepotential 38 involve risksand uncertainties 38 STARLIMS filings 38 MMRGlobal Inc. 38 § #a [002] 38 5 lipoxygenase inhibitor 38 consents authorizations 38 Cytokinetics specified 38 Mediaseed R 38 others Mannatech inability 37 Nephros Annual Report 37 TRUSTCASH 37 #,#,# #,#,# -shameful betrayal 37 Tekmira disclaims any 37 transport cystine 37 - Operating Expenses [001] 37 visit www.ethosfr.com 37 Voxware filings 37 Including newbuildings 37 postretirement benefit 37 ARLP Partnership 37 NJSA #:#-# [002] 37 Western Keltic shareholders 37 referenced investigational 37 APDN SEC 37 punitive incidental 37 Companys 37 USED IN FINANCING ACTIVITIES 37 redundancy scalability 37 CFR § #.# [006] 37 o h 37 - -Commey 37 Colihues tailings impoundment 37 payor acceptance 37 t h r 37 #,#,# #,#,# #,#,# #,#,# [001] 37 ImmunoGen Annual Report 37 thoseexpressed 37 results todiffer materially 37 expressed orimplied 37 Shigamabs 37 CoTherix logo 37 uncertainties materialize Shire 37 calcium hypochlorite markets 37 Partially offsetting 37 taxation socio 37 hong kong > 37 § #-#-# b [003] 37 Innodata Isogen acquires 37 subsidiaries Kindred Brookdale 37 fluctuations cyclicality 37 Indevus undertakes 37 XenoPort Quarterly Report 37 Generx TM 37 looking statements.These 37 Recommendation Statement 37 visit http:/www.chinawindsystems.com 37 Proteus Adonis Meridius IPAM 37 affect NYMET Holdings 37 e h r 37 website www.aeroflex.com 37 Furthermore ArQule 37 execute supplemental indenture 37 PROCHIEVE ® 37 LOVE YOU ALL 37 str = i 37 Publication Classified Ad 37 delinquencies defaults 37 h y 37 ourbusiness 37 PROLOR filings 37 Variable annuities involve 37 pulls Darvon painkiller 37 indentures pursuant 37 #.#-# b [001] 37 Thelin tm 37 commercializing ArteFill 37 AIF identifies 37 Hyperactivity Disorder ADHD 37 INACCURACIES 37 Sensipar ® 37 -#,# -#,# -#,# -#,# [003] 37 Comarco Announces 37 #,#,# Commitments 37 CFR #.# [002] 37 innovative StarCured R 37 unforeseen calamities 37 concerning Alexza 37 symbol PEH 37 Somatuline R Depot 37 Acapodene R 37 TFC receivables 37 adverse publicity 37 www.orchidcellmark.com 37 BigBand periodic 37 Mircette R 37 website GreenGainers 37 incorporate CXA 37 Factors Affecting Future 37 website www.nyandcompany.com 37 rapid technological advances 37 prescription brands RESTYLANE 37 w l 37 involve risks anduncertainties 37 R DYNACIN R 37 b Reflects 37 AMPS Risk 37 itsproducts 37 credit carryforwards 37 Congoleum undertakes 37 AMETEK filings 37 concerning Wowjoint 37 Icefloe 37 http:/www.tripos.com 37 obligations thereunder 37 affecting IsoTis 37 Shanghai EaseNet 37 InterRent publicly 37 USC § #u 37 fighter jets del Rosario 37 Reported Unaudited Condensed 37 h u 37 postretirement 37 viii insufficient 37 optimization seasonality 37 subordinated indebtedness 37 footwear apparel accessories 37 please visit www.middlebrookpharma.com 37 CFR § #.# [004] 37 early extinguishments 37 affecting O2Micro 37 p r 37 EVLT R procedure 37 Erythropoietic therapies may 37 services visit www.networkengines.com 37 Limited NNL 37 factors thatcould 37 prescribing olanzapine 37 hpSCs avoid ethical 37 Zi OEM 37 RISKS AND UNCERTAINTIES 37 men bisexuals transgender 37 reflect VIQ Solutions 37 manufactures VIVITROL ® 37 Quantitative Disclosures About 37 acquisitions dispositions 37 e mail lifestyle@readingeagle.com 37 NNL failure 37 Adolor Reports 37 inflammatory autoimmune diseases 37 visit http:/www.cytrx.com 37 risks uncertainties 37 drawing painting gouache 37 InnSuites Hotels 37 Partnered Brands segment 37 acquisitions mergers dispositions 37 forward lookingstatements 37 Convertible Notes tendered 37 Radware filings 37 OTI Annual Report 37 regulatory approvals 37 regulatory approvals Introgen 37 Rosetta dependence 37 Demographers attributed 37 TSX Venture AHR 37 Canexus LP 37 bioMETRX filings 37 @ y qW 37 Metalline Annual Report 37 AvenEx 37 goals expectations anticipations 37 adversely impact 37 Vion Form 37 Yucheng filings 37 attaching thereto 37 compliance therewith 37 specifically Axonyx 37 historicalfacts 37 Heska filings 37 rights xix xx 37 indications Cytokinetics 37 distinguishing MDCE products 37 XL# XL# XL# XL# 37 illiquid restricted 37 LogicVision disclaims 37 include ClindaReach TM 37 counterparty creditworthiness 37 generic Copaxone 37 ADSI filings 37 Aspyra actual 37 LOPROX R 37 alemtuzumab MS 37 Tucows filings 37 Colo. Sess 37 TRISENOX ® 37 futureevents 37 xii Type 37 CFRA forensic accounting 37 servicemark risks xiii 37 BioGlue R 37 payer reimbursement 37 bone marrow fibrosis 37 f o 37 VIACOM INC. AND SUBSIDIARIES 37 pharmacogenomic tests 37 impair Lillian Vernon 37 Ceragenin ™ technology 37 Administaff filings 36 SOLODYN R 36 Discovery Labs 36 - -seemingly unquenchable 36 STRIANT ® 36 Toreador intends 36 collaborations Pharmacopeia 36 todiffer materially 36 Ningbo Yuming 36 ofany 36 RXi Pharmaceutical Corporation 36 OTHER INCOME EXPENSES 36 R Digirad Imaging 36 indemnification obligations 36 Risks Factors 36 FERC MPSC NRC 36 Pervasip actual 36 applicable Offering Memorandum 36 OCGA § #-#-# [005] 36 B. Neal Auction 36 NASD Marketplace Rule 36 http:/www.nansulate.com 36 incorporating FalconStor 36 Offerors Commercial applies 36 forecasted timelines 36 Exelixis compounds 36 event reporting Clintrace 36 APPY believes 36 g r 36 ii Immtech ability 36 USC § #f 36 Complete Liquidation 36 reduced workforces scarcity 36 Bo Scaife TE 36 Bioenvision compounds under 36 Multiplied Media announces 36 Continuous Disclosure Defaults 36 newproducts 36 Invitel Holdings operates 36 website www.cmvt.com 36 Date xiv 36 Isis Alnylam 36 persons soliciting proxies 36 TeamStaff GS 36 professionals technological obsolescence 36 MergerSub 36 intellectual property infringement 36 Lannett Annual Report 36 Biogold Fuels 36 mergers consolidations 36 partially mitigated 36 forwarda ^ looking 36 satellite datacasting market 36 Pixelplus cautions readers 36 iv IBC 36 Univest Corporation files 36 IoGen 36 Risk Factors Relating 36 Trofex ™ 36 Scheduler Plus 36 prepetition liabilities 36 Infor expressly disclaims 36 Azedra TM Onalta TM 36 Xechem Nigeria 36 en actions ordinaires 36 Statement Statements 36 Note Movie showtimes 36 xviii currency 36 Markland Technologies filings 36 expectations anticipations estimates 36 Theragenics Corporation 36 Agreement constitutes discloseable 36 reflect Ronn Motor 36 commercialize BiDil 36 MFA MBS 36 Research CECR 36 bulk amorphous alloys 36 TrueKnowledge Platform TM 36 Analyte Specific Reagent 36 proprietary capillary aerosolization 36 transportation storage terminalling 36 objectives expectations anticipations 36 EPRI conducts 36 Plastic2Oil sites 36 Acorda Therapeutics filings 36 Nymox filings 36 dd DISCOUNTS R 36 integrate restructurings consolidations 36 Kosan dependence 36 - + [008] 36 GulfMark filings 36 CFR § #.# [005] 36 #.#-# Equal Opportunity 36 assorted pigments resins 36 Transcept periodic 36 Aeolus Pharmaceuticals Announces 36 Kanis JA 36 Portfolio Turnover 36 revise anyforward looking 36 mGluR2 mGluR4 mGluR5 mGluR7 36 h o 36 transgenically produced product 36 assume NO RESPONSIBILITY 36 renegotiation nullification 36 Shire plc filings 36 EGI Acquisition LLC 36 Sunesis clinical trials 36 xv adverse 36 relative illiquidity 36 inability 36 o t 36 § #-#-# [005] 36 Medtronic periodic 36 contingent liabilities 36 SiriCOMM periodic reports 36 within themeaning 36 gathering compressing treating 36 BioGold Fuels 36 supplemental indenture containing 36 InPath TM System 36 Powerbase Companies 36 xxiii fluctuations 36 update anyforward looking 36 y r 36 Irinotecan Hydrochloride Injection 36 CETCO Colloid Environmental 36 Somewhat mitigating 36 UMZ deposit 36 difficulties foreseeing 36 damage cirrhosis liver 36 andrelated 36 rheumatoid arthritis thrombocytopenia 36 Defendants misrepresented 36 thepossibility 36 uninsurable risks 36 Modifiable risk 36 kumar singh mam im 36 Midwest Consent Decree 36 Effective Date #.# 36 Metalink Annual Report 36 Lordsburg Mining District 36 acquisitions divestitures mergers 36 intellectual property litigations 36 RPTN common 36 Macrovision assumes 36 valuation allowances 36 See www.chdtcorp.com 36 Innotrac Website www.innotrac.com 36 uncollectability 36 Medtronic Annual Report 36 scale oligo synthesis 36 andmarket 36 mortality persistency 36 hypertension coronary 36 I. Item 1A 36 Multiemployer Pension Plan 36 mature physiologically relevant 36 ELADUR 36 subvented APR 36 please visit www.rexahn.com 36 Inovio Annual Report 36 evaluating bafetinib 36 Unearned Premiums 36 indentures governing 36 microsurgical disciplines